p300 (phospho Ser89) rabbit pAb

SKU: ES5121

Size: 100μL

Source:Rabbit

Applications:IHC;IF;ELISA

Reactivity:Human;Mouse;Rat

Dilution:Immunohistochemistry: 1/100 - 1/300. ELISA: 1/5000. Not yet tested in other applications.

Immunogen:The antiserum was produced against synthesized peptide derived from human p300 around the phosphorylation site of Ser89. AA range:55-104

Storage_stability:-20°C/1 year

Clonality:Polyclonal

Isotype:IgG

Concentration:1 mg/ml

Observed_band(KD):

Human_gene_id:2033

Human_swiss_prot_no:Q09472

Subcellular_location:Cytoplasm . Nucleus . Chromosome . Localizes to active chromatin: Colocalizes with histone H3 acetylated and/or crotonylated at 'Lys-18' (H3K18ac and H3K18cr, respectively) (PubMed:25818647). In the presence of ALX1 relocalizes from the cytoplasm to the nucleus. Colocalizes with ROCK2 in the nucleus (PubMed:12929931). .

Other_name:EP300; P300; Histone acetyltransferase p300; p300 HAT; E1A-associated protein p300

Background:E1A binding protein p300(EP300) Homo sapiens This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008],